Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Telo Genomics Corp (OP: TDSGF ) 0.1360 +0.0012 (+0.89%) Streaming Delayed Price Updated: 1:54 PM EDT, Jul 15, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Telo Genomics Corp Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030 January 30, 2024 EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END Via FinancialNewsMedia Telo Genomics Completes International Standards Organization ("ISO") 15189 Final Accreditation October 26, 2023 Toronto, Ontario--(Newsfile Corp. - October 26, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce... Via Newsfile Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030 October 17, 2023 EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NASDAQ:GH),(NASDAQ:NTRA),(NYSE:DGX),(NASDAQ:NEO) EQNX::TICKER_END Via FinancialNewsMedia Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030 January 30, 2024 From FN Media Group LLC Via GlobeNewswire Telo Genomics Announces Clinical Launch of Non-Invasive Cancer Diagnostic, TeloViewSMM – An Important Commercial Milestone Achieved October 17, 2023 TeloView Analyses Telomeres to Accurately Predict and Characterize Multiple Myeloma Toronto, ON – October 17, 2023 – Telo Genomics Corp. (OTCQB: TDSGF) (TSXV: TELO) (the “Company” or “Telo”) today... Via FinancialNewsMedia Topics Artificial Intelligence Exposures Artificial Intelligence Telo Genomics Presents Positive Results in Assessing MRD in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting October 12, 2023 Toronto, ON – October 12, 2023 – Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “TELO”) is pleased to announce that it has participated in the International Myeloma Society (“IMS”)... Via FinancialNewsMedia Telo Genomics Announces Achieving Interim Results from Smouldering Myeloma Clinical Study September 14, 2022 Toronto, Ontario--(Newsfile Corp. - September 14, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is... Via Newsfile Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
